J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
B e s i l e s o m a b
3 l a n g u a g e s
● ا ل ع ر ب ي ة ● C a t a l à ● N e d e r l a n d s
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Whole antibody
Mouse
CEA -related antigen
Scintimun
Besilesomab (trade name Scintimun ) is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m . It is used to detect inflammatory lesions and metastases .[1] immunoglobulin , IgG1 isotype . SCINTIMUN has been used since 1992 mainly in Hungary, Czech Republic, and Switzerland on the basis of local marketing authorizations, and in Germany (on the basis of individual prescription). Between 1992 and 2009, an estimated 90,000 patients has been studied. In 2009, the EMEA has approved SCINTIMUN for marketing in all European countries.[2] [3]
References [ edit ]
^ "Positive opinion of the CHMP for SCINTIMUN (Besilesomab)" (PDF) . European Medicines Agency . 22 October 2009. Archived from the original (PDF) on December 25, 2009.
Atorolimumab
Avelumab
Avdoralimab
Belimumab
Bleselumab
Brodalumab
Camidanlumab tesirine
Carlumab
Cemiplimab
Dupilumab
Eldelumab
Emapalumab
Fresolimumab
Golimumab
Ianalumab †
Lanadelumab
Lenzilumab
Lerdelimumab
Lirentelimab
Lirilumab
Mavrilimumab
Metelimumab
Morolimumab
Namilumab
Oleclumab
Oxelumab §
Pamrevlumab
Placulumab
Relatlimab †
Sarilumab
Sifalimumab
Tabalumab
Tezepelumab
Ulocuplumab
Varlilumab
Elsilimomab
Faralimomab
Gavilimomab
Inolimomab
Maslimomab
Nerelimomab
Odulimomab
Telimomab aritox
Vepalimomab
Zolimomab aritox
Basiliximab
Clenoliximab
Galiximab
Gomiliximab
Infliximab
Keliximab
Lumiliximab
Priliximab
Teneliximab
Vapaliximab
Aselizumab
Atezolizumab
Benralizumab
Camrelizumab †
Cedelizumab
Certolizumab pegol
Crizanlizumab
Daclizumab
Eculizumab
Efalizumab ‡
Epratuzumab
Erlizumab
Etrolizumab †
Fontolizumab
Frexalimab †
Inebilizumab
Itolizumab
Lampalizumab †
Letolizumab
Ligelizumab †
Lulizumab pegol
Mepolizumab
Mogamulizumab
Natalizumab
Ocrelizumab
Omalizumab
Ozoralizumab
Pascolizumab
Pateclizumab
Pembrolizumab
Pexelizumab
Pidilizumab
Plozalizumab
PRO 140 †
Quilizumab
Ravulizumab
Reslizumab
Retifanlimab
Rontalizumab
Rovelizumab
Ruplizumab
Samalizumab
Satralizumab
Siplizumab
Spartalizumab †
Talizumab
Teclistamab
Teplizumab
Tislelizumab
Tocilizumab
Toralizumab
Tregalizumab
Vatelizumab
Vedolizumab
Visilizumab
Vobarilizumab
TGN1412 §
Immune activation : Dostarlimab Other: Ibalizumab
Rozanolixizumab
Sutimlimab
Canakinumab
Fezakinumab
Fletikumab
Guselkumab
Secukinumab
Sirukumab
Tralokinumab
Ustekinumab
Bimekizumab
Clazakizumab
Gevokizumab
Ixekizumab
Mirikizumab †
Lebrikizumab
Olokizumab †
Perakizumab
Risankizumab
Spesolimab
Tildrakizumab
Sulesomab
t
e
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Besilesomab&oldid=1084697057 " C a t e g o r i e s : ● D r u g s n o t a s s i g n e d a n A T C c o d e ● T e c h n e t i u m c o m p o u n d s ● M o n o c l o n a l a n t i b o d y s t u b s ● A n t i n e o p l a s t i c a n d i m m u n o m o d u l a t i n g d r u g s t u b s H i d d e n c a t e g o r i e s : ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● A r t i c l e s w i t h c h a n g e d C A S N o i d e n t i f i e r ● C h e m i c a l s t h a t d o n o t h a v e a C h e m S p i d e r I D a s s i g n e d ● A r t i c l e s w i t h c h a n g e d K E G G i d e n t i f i e r ● A r t i c l e s w i t h o u t E B I s o u r c e ● C h e m i c a l p a g e s w i t h o u t D r u g B a n k i d e n t i f i e r ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● D r u g s w i t h n o l e g a l s t a t u s ● D r u g h a s E M A l i n k ● D r u g b o x e s w h i c h c o n t a i n c h a n g e s t o v e r i f i e d f i e l d s ● D r u g s t h a t a r e a m o n o c l o n a l a n t i b o d y ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 2 6 A p r i l 2 0 2 2 , a t 0 1 : 4 5 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
N
